{"denoms":[{"counts":[{"groupId":"BG000","value":"477"},{"groupId":"BG001","value":"478"},{"groupId":"BG002","value":"955"}],"units":"Participants"}],"groups":[{"description":"Participants received bortezomib in combination with melphalan and prednisone for nine 42-day cycles. Bortezomib was administered either IV or subcutaneously at 1.3 mg/m² during cycles 1 to 4 on days 1, 4, 8, 11, 22, 25, 29, and 32 followed by 1.3 mg/m² during cycles 5 to 9 on days 1, 8, 22, and 29. On days 1 to 4 of each cycle, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².","id":"BG000","title":"Bortezomib, Melphalan, Prednisone"},{"description":"Participants received carfilzomib administered in combination with melphalan and prednisone for nine 42-day cycles. Carfilzomib was administered as an intravenous (IV) infusion on days 1, 2, 8, 9, 22, 23, 29, and 30 of each 42-day cycle. The carfilzomib dose was at 20 mg/m² on cycle 1, days 1 and 2 followed by 36 mg/m² thereafter. On days 1 to 4, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².","id":"BG001","title":"Carfilzomib, Melphalan, Prednisone"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"6.5","value":"71.5"},{"groupId":"BG001","spread":"5.7","value":"72.0"},{"groupId":"BG002","spread":"6.1","value":"71.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"238"},{"groupId":"BG001","value":"235"},{"groupId":"BG002","value":"473"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"239"},{"groupId":"BG001","value":"243"},{"groupId":"BG002","value":"482"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"33"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"443"},{"groupId":"BG001","value":"427"},{"groupId":"BG002","value":"870"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"52"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}],"title":"American Indian or Alaska Native"},{"categories":[{"measurements":[{"groupId":"BG000","value":"121"},{"groupId":"BG001","value":"123"},{"groupId":"BG002","value":"244"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"339"},{"groupId":"BG001","value":"329"},{"groupId":"BG002","value":"668"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}],"title":"Multiple"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"31"}]}],"title":"Not Reported"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"99"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"194"}]}],"title":"Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"378"},{"groupId":"BG001","value":"383"},{"groupId":"BG002","value":"761"}]}],"title":"Stage II or III"}],"description":"The International Staging System (ISS) for myeloma was published by the International Myeloma Working Group:\n\n* Stage I: β2-microglobulin (β2M) \\< 3.5 mg/L, albumin \\>= 3.5 g/dL\n* Stage II: β2M \\< 3.5 mg/L and albumin \\< 3.5 g/dL; or β2M 3.5 mg/L - 5.5 mg/L irrespective of the serum albumin\n* Stage III: β2M ≥ 5.5 mg/L","paramType":"NUMBER","title":"Stratification Factor: International Staging System (ISS) Stage","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"123"},{"groupId":"BG001","value":"123"},{"groupId":"BG002","value":"246"}]}],"title":"Intravenous"},{"categories":[{"measurements":[{"groupId":"BG000","value":"354"},{"groupId":"BG001","value":"355"},{"groupId":"BG002","value":"709"}]}],"title":"Subcutaneous"}],"description":"The route of bortezomib administration (IV versus SC) was made per investigator's choice, dose modification, or regulatory approval. The investigator selected the route for all participants prior to randomization to treatment group in order to minimize any evaluation bias because of imbalances in potential prognostic factors that might have impacted the investigator's choice of a particular route.","paramType":"NUMBER","title":"Stratification Factor: Route of Bortezomib Administration","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"141"},{"groupId":"BG001","value":"140"},{"groupId":"BG002","value":"281"}]}],"title":"Asia Pacific"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"20"}]}],"title":"North America"},{"categories":[{"measurements":[{"groupId":"BG000","value":"317"},{"groupId":"BG001","value":"320"},{"groupId":"BG002","value":"637"}]}],"title":"Europe"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"17"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Stratification Factor: Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"329"},{"groupId":"BG001","value":"327"},{"groupId":"BG002","value":"656"}]}],"title":"< 75 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"151"},{"groupId":"BG002","value":"299"}]}],"title":"≥ 75 years"}],"paramType":"NUMBER","title":"Stratification Factor: Age","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"125"},{"groupId":"BG001","value":"129"},{"groupId":"BG002","value":"254"}]}],"title":"0 (Fully active)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"250"},{"groupId":"BG001","value":"260"},{"groupId":"BG002","value":"510"}]}],"title":"1 (Restrictive but ambulatory)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"89"},{"groupId":"BG002","value":"190"}]}],"title":"2 (Ambulatory but unable to work)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"title":"Missing"}],"description":"Eastern Cooperative Oncology Group (ECOG) Performance Status is used by doctors and researchers to assess how a participants disease is progressing, assess how the disease affects the daily living activities of the participant and determine appropriate treatment and prognosis. 0 = Fully Active; 1 = Restricted activity but ambulatory; 2 = Ambulatory but unable to carry out work activities; 3 = Limited Self-Care; 4 = Completely Disabled, no self-care, confined to bed or chair; 5 = Dead.","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"participants"}]}